Summary
Cyclosporine (Cy) binds to lipoproteins in plasma. In order to test if its pharmacokinetics would be modified when efficient lipid-lowering treatment is introduced, a study has been done of Cy pharmacokinetics and any interaction with the lipid-lowering agent fenofibrate in hyperlipidaemic long-term, survivors of heart transplantation. Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng·ml−1), Cmax (812 ng·ml−1 by RIA and 757 ng·ml−1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).
The only adverse effect was an increase in creatinine (157 vs 145 mmol/l). Further studies are needed to investigate the mechanism of Cy-fenofibrate nephrotoxicity and to evaluate the long-term efficiency and safety of fenofibrate after heart transplantation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Billingham ME (1987) Cardiac transplant atherosclerosis. Transplant Proc 19: 19–25
Stamler JS, Vaughan DE, Rudd A, Mudge GH, Kirshenbaum J, Young P, Alexander RW, Loscalzo J (1988) Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 62: 1268–1272
Rudas L, Pflugfelder PW, McKenzie N, Menkis AH, Novick RJ, Kostuk WJ (1990) Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 66: 1135–1138
Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM, Young JB (1989) Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53–56
Jevnikar AM, Petric R, Holub BJ, Philbrick DJ, Clark WF (1988) Effect of cyclosporine on plasma lipids and modification with dietary fish oil. Transplantation 46: 722–725
Ettinger WH, Dysko RC, Clarkson TB (1989) Prednisone increases low density lipoprotein in cynomolgus monkeys fed saturated fat and cholesterol. Arteriosclerosis 9: 848–855
De Lorgeril M, Dureau G, Guidollet J, Boissonnat P, Renaud S (1990) Prevalence of dyslipidemia in long-term survivors of heart transplantation. Eur Heart J 11: 176
Ryffel B, Donatsch P, Madörin M, Matter BE, Rüttimann G, Schön H, Stoll R, Wilson J (1983) Toxicological evaluation of cyclosporin A. Arch Toxicol 53: 107–141
Kahan BD (1989) Cyclosporine. New Engl J Med 321: 1725–1738
Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharmacol 34: 715–718
Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM (1987) Effects of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Am J Med 83: 75–84
Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Grundy SM, Knopp RH, Lasser NL, Mellies MJ, Palmer RH, Samuel P, Schonfeld G, Superko HR (1986) Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 6: 670–678
Bizollon CA, Cohen R (1990) French interlaboratory cyclosporine quality assesment scheme. Nucl Med Biol 17: 737–744
Ball PE, Munzer H, Keller HP, Abisch E, Rosenthaler J (1988) Specific H Radioimmunoassay with a monoclonal antibody for monotoring cyclosporine in blood. Clin Chem 34: 257–261
Garaffo R, Lapalus P (1985) Simplified liquid chromatographic analysis for cyclosporine A in blood and plasma with use of rapid extraction. J Chromatogr 337: 416–422
Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Editorial: standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7
Kahan BD (1985) Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40: 457–476
Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring (1987) Clin Chem 33: 1269–1288
Venkataramanan R, Burckart GJ, Ptachcinski RJ, Lee A, Hardesty RL, Griffith BP (1986) Cyclosporine pharmacokinetics in heart transplant recipients. Transplant Proc 4: 768–770
Brockmöller J, Neumayer HH, Wagner K, Weber W, Heinemeyer G, Kewitz H, Roots I (1990) Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 38: 237–242
Lindholm A, Henricsson S, Gang P (1988) The free fraction of cyclosporine in plasma: clinical findings with a new method. Transplant Proc 20: 377–381
Freed BM, Rosano TG, Lempert N (1987) In vitro immunosuppressive properties of cyclosporine metabolites. Transplantation 43: 123–127
Kunzendorf U, Brockmöller J, Jochimsen F, Roots I, Offermann G (1989) Immunosuppressive properties of cyclosporine metabolites. Lancet 1: 734–735
Rössenr S, Orö L (1981) Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate. Atherosclerosis 38: 273–282
Kobashigawa JA, Murphy FL, Stevenson LW et al. (1990) Lowdose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 82 [Suppl IV]: IV 281-IV 283
De Groen PC, Wiesner RH, Krom RAF (1988) Cyclosporine Ainduced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay? Transplant Proc 20: 374–376
Author information
Authors and Affiliations
Additional information
Michel de Lorgeril is a fellow from la Fondation pour la Recherche Médicale
Rights and permissions
About this article
Cite this article
deLorgeril, M., Boissonnat, P., Bizollon, C.A. et al. Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Eur J Clin Pharmacol 43, 161–165 (1992). https://doi.org/10.1007/BF01740664
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01740664